CD63 antibody
Quick Overview for CD63 antibody (ABIN6654892)
Target
See all CD63 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Purified
-
Purity
- Protein A affinity chromatography
-
Immunogen
- Recombinant human full-length protein was used as the immunogen for the recombinant CD63 antibody.
-
Isotype
- IgG kappa
-
-
-
-
Application Notes
-
Optimal dilution of the recombinant CD63 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 1-2 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1) -
Restrictions
- For Research Use only
-
-
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant CD63 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- CD63
-
Alternative Name
- CD63 / LAMP-3
-
Background
- This mAb recognizes protein of 26 kDa-60 kDa, which is identified as CD63/LAMP-3. The tetraspanins are integral membrane proteins expressed on cell surface and granular membranes of hematopoietic cells and are components of multi-molecular complexes with specific integrins. The tetraspanin CD63/LAMP-3 is a lysosomal membrane glycoprotein that translocates to the plasma membrane after platelet activation. It is expressed on activated platelets, monocytes and macrophages, and is weakly expressed on granulocytes, T cell and B cells. It is located on the basophilic granule membranes and on the plasma membranes of lymphocytes and granulocytes. CD63 is a member of the TM4 superfamily of leukocyte glycoproteins that includes CD9, CD37 and CD53, which contain four transmembrane regions. CD63/LAMP-3 may play a role in phagocytic and intracellular lysosome-phagosome fusion events. Deficiency is associated with Hermansky-Pudlak syndrome and is strongly expressed during the early stages of melanoma progression.
Target
-